Covaxin: Indigenous Vaccine for COVID-19
Covaxin is India's first vaccine candidate to have gone into human clinical trials. It is developed by Bharat Biotech and has been approved by the Drug Controller General of India (DCGI) for phase I and II human clinical trials.
- The SARS-CoV-2 strain was isolated in National Institute of Virology (NIV), Pune and transferred to Bharat Biotech. They developed Covaxin as an “inactivated” vaccine — one made by using particles of the Covid-19 virus that were killed, making them unable to infect or replicate. Injecting particular doses of these particles serves to build immunity by helping the body create antibodies against ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 Transformation of Food Systems: Balancing Food, Environment & Climate Crisis
- 2 Emerging Carbon Management Technologies: Strategic Solutions for a Net-Zero Future
- 3 Soil Health Impacts of Climate Change & Fertilisers Misuse
- 4 Deep-Tech Revolution: Transforming Global Agriculture
- 5 Integrated and Scientific River Management in India
- 6 Global Ethical Framework for Neurotechnology
- 7 Rethinking India’s Inflation Targeting Framework
- 8 Impact of Digital Tradecraft on Terror Networks
- 9 IMF Assessment of India’s National Accounts Data: Key Concerns and Implications
- 10 G20 Summit: High Ambition, Weak Cohesion
